<instructions>Your goal is to analyze the following comment and estimate how highly it will be upvoted by the Hacker News community.</instructions><comment><author>andylynch</author><text>Especially in the next few months, supply of all of these will be limited by production capacity and supply chains.  Having multiple available means more doses can be delivered sooner.</text><parent_chain><item><author>dvfjsdhgfv</author><text>If they actually get to 90% or more, why would anyone bother with the more expensive and cumbersome vaccines? Except that the EU already signed a deal to buy the vaccines from AstraZeneca, Sanofi and Johnson &amp;amp; Johnson.</text></item><item><author>bawolff</author><text>Maybe for less developed countries, but i think for major economies, the price difference is insignificant relative to the benefits of any vaccine.</text></item><item><author>throwawayiionqz</author><text>Another huge differentiator is price. At $3 to $4, many countries will jump on board ASAP and stay away from the expensive vaccines from Pfizer and Moderna.</text></item><item><author>mcdowall</author><text>The key differentiator here is the storage requirements (2-8c ‘normal refrigerator’).&lt;p&gt;That’s much more accessible to developing &amp;#x2F; low GDP countries as opposed the cumbersome and expensive storage requirements of the other two.</text></item></parent_chain></comment><story><title>Oxford University breakthrough on global COVID-19 vaccine</title><url>https://www.ox.ac.uk/news/2020-11-23-oxford-university-breakthrough-global-covid-19-vaccine</url></story>
<instructions>Your goal is to analyze the following comment and estimate how highly it will be upvoted by the Hacker News community.</instructions><comment><author>ulfw</author><text>Because 95% efficacy is twice as good as 90%. And some people are willing to pay the $30 it costs to be 5% likelihood to have a non-functioning vaccine vs. a 10% likelihood the vaccine you just got won&amp;#x27;t work on you.</text><parent_chain><item><author>dvfjsdhgfv</author><text>If they actually get to 90% or more, why would anyone bother with the more expensive and cumbersome vaccines? Except that the EU already signed a deal to buy the vaccines from AstraZeneca, Sanofi and Johnson &amp;amp; Johnson.</text></item><item><author>bawolff</author><text>Maybe for less developed countries, but i think for major economies, the price difference is insignificant relative to the benefits of any vaccine.</text></item><item><author>throwawayiionqz</author><text>Another huge differentiator is price. At $3 to $4, many countries will jump on board ASAP and stay away from the expensive vaccines from Pfizer and Moderna.</text></item><item><author>mcdowall</author><text>The key differentiator here is the storage requirements (2-8c ‘normal refrigerator’).&lt;p&gt;That’s much more accessible to developing &amp;#x2F; low GDP countries as opposed the cumbersome and expensive storage requirements of the other two.</text></item></parent_chain></comment><story><title>Oxford University breakthrough on global COVID-19 vaccine</title><url>https://www.ox.ac.uk/news/2020-11-23-oxford-university-breakthrough-global-covid-19-vaccine</url></story>